Get to know our clinical trials

A phase 2, randomised, multi-centre, open label trial to evaluate the safety and efficacy of intravesical nadofaragene firadenovec alone or in combination with chemotherapy (gemcitabine and docetaxel) or immunotherapy (pembrolizumab) in subjects with high-grade Bacillus Calmette-Guerin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC)

Imagen del Dr. Felipe Villacampa, urólogo de la Clínica Universidad de Navarra. Dedicación preferencial a la Urooncología, especialmente tumores de vejiga, riñón y testículo. Fertilidad masculina.
Dr. Felipe Villacampa Curriculum
Specialist Urology Department
Madrid headquarters
Cancer Center
Urological Cancer Area
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase

Technical Summary

  • A PHASE 2, RANDOMISED, MULTI-CENTRE, OPEN LABEL TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVESICAL NADOFARAGENE FIRADENOVEC ALONE OR IN COMBINATION WITH CHEMOTHERAPY (GEMCITABINE AND DOCETAXEL) OR IMMUNOTHERAPY (PEMBROLIZUMAB) IN SUBJECTS WITH HIGH-GRADE BACILLUS CALMETTE-GUERIN (BCG) UNRESPONSIVE NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)
  • Code EudraCT: 2024-512177-27-00
  • Protocol number: 000434
  • Promoter: Ferring Pharmaceuticals
  • Molecule/Drug: nadofaragene firadenovec intravesical
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION